- HK$163.45m
- HK$498.42m
- HK$336.11m
Annual income statement for PuraPharm, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 660 | 448 | 407 | 382 | 336 |
| Cost of Revenue | |||||
| Gross Profit | 423 | 263 | 219 | 205 | 180 |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 750 | 543 | 482 | 387 | 350 |
| Operating Profit | -90.2 | -95 | -74.8 | -5.12 | -13.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -117 | -119 | -102 | -29.1 | -34.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -122 | -120 | -106 | -35.4 | -35.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -122 | -120 | -106 | -35.4 | -35.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -122 | -120 | -106 | -35.4 | -35.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.293 | -0.377 | -0.23 | -0.11 | -0.076 |